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Abstract 
Background: Aspirin resistance established by different laboratory methods is still a debated problem. Using COX1 
specific methods no aspirin resistance was detected among healthy volunteers. Here we tested the effect of chronic 
aspirin treatment on platelets from patients with stable coronary artery disease. The expression of COX2 mRNA in 
platelets and its influences on the effect of aspirin was also investigated.
Methods: One hundred and forty four patients were enrolled in the study. The direct measurement of COX1 acetyla-
tion was carried out by monoclonal antibodies specific to acetylated and non-acetylated COX1 (acCOX1 and nac-
COX1) using Western blotting technique. Arachidonic acid (AA) induced TXB2 production by platelets was measured 
by competitive immunoassay. AA induced platelet aggregation, ATP secretion and VerifyNow Aspirin Assay were also 
performed. COX2 and COX1 mRNA expression in platelets were measured in 56 patients by RT-qPCR.
Results: In 138 patients only acCOX1 was detected, in the remaining six patients nacCOX1 disappeared after a 
compliance period. AA induced TXB2 production by platelets was very low in all patients including the 6 patients after 
compliance. AA induced platelet aggregation, secretion and with a few exceptions the VerifyNow Assay also demon-
strated the effect of aspirin. Smoking, diabetes mellitus and inflammatory conditions did not influence the results. The 
very low amount of COX2 mRNA detected in 39 % of the investigated platelets did not influence the effect of aspirin.
Conclusions: No aspirin resistance was detected among patients with stable coronary artery disease. COX2 expres-
sion in platelets did not influence the effect of aspirin.
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Background
Since the middle of the last century low dose aspirin 
(acetylsalicylic acid) has been effectively used in the pre-
vention of acute atherothrombotic complications, like 
myocardial infarction and atherothrombotic ischemic 
stroke [1–5]. It prevents vascular death and nonfatal vas-
cular events by approximately 15 and 30 %, respectively 
[1–3, 6]. The antithrombotic effect of aspirin is primar-
ily due to its anti-platelet action. Aspirin as an acetylating 
agent acetylates the Ser529 residue of cyclooxygenase-1 
(COX1), which is located in the wall of the enzyme’s 
active-site pocket [6–8]. Arachidonic acid (AA) released 
from membrane phospholipids as the result of signaliza-
tion by platelet agonists, is transformed by COX1, exert-
ing both cyclooxygenase and peroxidase activities, into 
cyclic endoperoxides, prostaglandin G2 and H2. The latter 
is the precursor of the powerful platelet activating pros-
taglandin derivative, thromboxane A2 (TXA2). The cova-
lent modification of Ser529 prevents the access of AA to 
the active site of COX-1 and blocks TXA2 production by 
platelet throughout its lifespan.
In certain patients low dose aspirin therapy is not effec-
tive in preventing acute atherothrombotic complica-
tions, and for this reason the term “aspirin resistance” was 
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introduced. In the PubMed browsing this term resulted in 
over 2000 publications. True aspirin resistance is the inabil-
ity of aspirin to acetylate Ser259 residue in platelet COX1. 
The ineffectiveness of aspirin in protecting an individual 
from acute vascular events is often considered “aspirin 
resistance” although such cases are very likely related to 
the fact that aspirin inhibits effectively and selectively only 
one out of several pathways leading to platelet activation [9, 
10]. It fails to inhibit platelet activation induced by strong 
agonists, like thrombin or high dose of collagen and only 
partially inhibits ADP induced platelet aggregation. The 
involvement of such stimuli in platelet activation could be 
prevalent in atherosclerotic vessel. In many studies non-
compliance was not adequately controlled and was not 
separated from aspirin resistance. Further problem was the 
lack of laboratory tests that specifically detect the acetyla-
tion of COX1. Non-responsiveness to aspirin as measured 
by laboratory tests non-specific for detecting the effect 
of aspirin was also confused with aspirin resistance. In a 
recent study we developed monoclonal antibodies react-
ing with acetylated and non-acetylated COX1 (acCOX1 
and nacCOX1, respectively) for the first time, and utiliz-
ing these antibodies a highly specific and sensitive method 
that detects 2.5  % of platelet nacCOX1 was developed 
[11]. Using this method that measures COX1 acetylation 
by aspirin directly, no aspirin resistance was found among 
108 healthy volunteers taking 100 mg enteric-coated aspi-
rin daily for 7  days. The same results were obtained by 
COX1-dependent functional tests, like AA-induced TXB2 
formation in platelet rich plasma (PRP), AA-induced plate-
let aggregation and the VerifyNow Aspirin Assay [11, 12]. 
Practically complete inhibition of TXB2 formation during 
coagulation of whole blood was also observed in 24 healthy 
volunteers after 7 days of aspirin treatment [13].
However, in patients with coronary artery dis-
ease (CAD) the situation might be different from that 
observed in healthy volunteers. There could be condi-
tions related to this disease, which might influence the 
effect of aspirin. The higher turnover of platelets and the 
expression/up-regulation of COX2, insensitive to low 
dose aspirin, have been claimed to contribute to impaired 
aspirin effect in diabetic patients and in inflammatory 
conditions [9, 14–17]. To explore the frequency of true 
aspirin resistance among patients with CAD 144 such 
patients being on long-term aspirin monotherapy were 
investigated for COX1 acetylation and tested for COX1 
dependent functional assays. The expression of COX2 in 
this patient population was also investigated.
Methods
Subjects
Patients who had undergone percutan coronary angio-
plasty or coronary artery bypass grafting surgery being 
on aspirin monotherapy for secondary prevention were 
enrolled in the study. The patients were regularly admit-
ted at the outpatient service of the Department of Car-
diology, University of Debrecen, Debrecen Hungary; 
study participants were enrolled within a 1.5-year period. 
They were taking 100 mg enteric-coated aspirin daily for 
at least 1  month before investigation. Exclusion criteria 
were: acute coronary syndrome or any other major clini-
cal event or infection in the previous 3  months, malig-
nant disorder, hyperthyroidism, autoimmune disease 
and chronic renal insufficiency, intake of antiplatelet 
drugs other than aspirin in the previous 2 weeks, known 
bleeding diathesis, anemia with hemoglobin value below 
100  g/L and platelet count below 100  G/L. Finally, 144 
patients were eligible for being involved in the study. The 
Jeffrey method was used for sample size calculation as 
described by Brown et  al. [18]. Apparently healthy con-
trols (n =  108) recruited for the study have been char-
acterized in a previous publication [11]. All individuals 
enrolled in the study gave written informed consent 
prior to their inclusion in the study. Ethical approval was 
obtained from the Ethics Committee of the Medical Fac-
ulty, University of Debrecen, Hungary and the study was 
performed in accordance with the ethical standards laid 
down in the 1964 Declaration of Helsinki and its later 
amendments.
Sample preparation
Blood samples were collected into Vacutainer tubes 
containing 0.109  mol/L trisodium citrate (Becton–
Dickinson, Franklin Lakes, NJ) after overnight fasting. 
Anticoagulated blood was directly used for the Veri-
fyNow® (VN) Aspirin assay (Accumetrics, San Diego, 
CA). Platelet rich plasma (PRP) separated by centrifu-
gation (120g, 37  °C, 15  min) was used for AA induced 
platelet aggregation tests. Platelet depleted plasma (PDP), 
was obtained by two consecutive centrifugations (1500g, 
25 °C, 20 min).
Methods used for the detection of aspirin effect
In a previous study we developed new methods for the 
direct and indirect detection of COX-1 acetylation by 
aspirin [11]. The first method is based on two monoclo-
nal antibodies raised against the acetylated and non-acet-
ylated nonapeptide that corresponded to human COX-1 
525-533 residues (H-Gly-Ala-Pro-Phe-Ser-Leu-Lys-Gly-
Leu-OH). Using the two purified antibodies nacCOX1 
and acCOX-1 could be clearly distinguished in the lysate 
of washed platelets by Western blotting technique.
The indirect method measures 0.25  mg/mL AA-
induced TXB2 generation in PRP diluted to 30 ×  109/L 
by PDP. The produced TXB2 was separated from AA 
and from other interfering substances by sequential solid 
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phase extraction [11]. In the final eluted sample TXB2 
concentration was measured by competitive immunoas-
say (Assay Designs, Ann Arbor, MI) and it was expressed 
as pg TXB2 produced by 106 platelets.
As among the generally used routine laboratory tests 
used for the detection of aspirin effect AA-induced 
platelet aggregation, ATP secretion and the VN Asprin 
assay were proven to be the most reliable tests [12], we 
also used these assays to detect the effect of aspirin on 
patients with CAD being on secondary prevention. VN 
Aspirin Assay was performed according to the manu-
facturer’s instructions and the results were expressed as 
Aspirin Reaction Units (ARU). Platelet aggregation and 
secretion in platelet rich plasma was induced by 500 µg/
mL AA (Helena, Gateshead, UK) and was monitored in 
Chrono-Log 700 lumiaggregometer (Chrono-Log, Haver-
town, PA) for 8 min. Prior to the experiments the platelet 
count was adjusted to 260  ×  109 platelet/L. Aggrega-
tion was expressed as the percentage of maximal change 
in light transmission (Δtransmission   %). ATP secretion 
was quantitated by bioluminescence method using lucif-
erin-luciferase reagent (Biothema AB, Handen, Sweden). 
Maximal ATP secretion was expressed as μmol ATP/1011 
platelets.
Measurement of COX1 and COX2 mRNA
COX1 and COX2 mRNA expression was determined in 
the platelets of 56 patients randomly selected out of the 
144 subjects with CAD. RNA was isolated from leukocyte 
depleted platelets as described earlier [19]. The integrity of 
RNA samples was shown by determining the GAPDH 3ʹ:5ʹ 
signal ratio [20], the absence of RNA contamination from 
white blood cells was proven by RT-qPCR analysis of each 
sample for CD15 and HLA-DQβ mRNAs [21]. Reverse 
transcription and RT-qPCR reaction were carried out as 
described by Zsóri et al. [19]. Briefly, First Strand cDNA 
Synthesis Kit (Roche, Mannheim, Germany) was used 
for reverse transcription. The reaction solution was incu-
bated at 42 °C for 60 min, and then at 94 °C for 5 min. No-
template control and no-reverse transcriptase controls 
included in each run showed negative results. The absence 
of contaminating DNA was also demonstrated by melting 
curve analysis. RT-qPCR reactions were carried out on 
LightCycler 480 (Roche) in duplicates using SYBR Green 
I Master (Roche). PCRs were set up in a final volume of 
20  µL consisting 10  µL Master Mix (2× concentration), 
5 µL of cDNA template derived from reverse-transcribed 
RNA and 300 nM primers for COX1 and 400 nM prim-
ers for COX2. The primer sequences were tccatgttggtggac 
tatgg (forward), gtggtggtccatgttcctg (reverse) for COX1, 
and cttcacgcatcagtttttcaag (forward), tcaccgtaaatatgatt-
taagtccac (reverse) for COX2. ACTB, GNAS and HDGF 
have been established as the most stable reference genes 
for the normalization of platelet mRNA expression in 
coronary artery disease; all three were amplified and used 
in the calculations [19]. The amplification program was: 
heating for 10 min at 95 °C, followed by 40 cycles of 10 s at 
95 °C, 30 s at 60 °C and 1 s at 72 °C. Melting curve analysis 
was performed between 66 and 95  °C in 0.11°C/s incre-
ments with 5 acquisitions/  °C. CT values, corresponding 
to the number of cycles at which the fluorescence sig-
nal exceeds a threshold value, were used for the relative 
gene quantification based on the method of Livak and 
Schmittgen [22]. ΔCT,COX1 and ΔCT,COX2 were established 
against each of the three reference genes and the mean 
ΔΔCT,COX1,COX2 values were used for the calculation of 
COX1 mRNA:COX2 mRNA ratios.
Results
The acetylation of COX‑1 by aspirin in patients with CAD
The characteristics of patients enrolled in the study are 
shown in Table  1. In the platelet lysate of 138 patients 
only acetylated COX1 was detected by Western blotting. 
These patients were represented by samples P1 and P2 
in Fig. 1. Previously it has been shown that the method 
is highly sensitive and could detect as low as 2.5  % of 
the total platelet COX1 in non-acetylated form [11], i.e. 
more than 97.5  % of platelet COX-1 was acetylated as 
the consequence of long term aspirin treatment. It is to 
be noted that in platelets from these treated patients no 
nacCOX1 could be detected, which contradicts an ear-
lier finding showing that only one monomer of the active 
dimeric enzyme is acetylated by aspirin [23]. In the case 
of six patients different amounts of non-acetylated COX1 
remained in the platelet lysate. Lanes P3/1 and P4/1 show 
the two extremes; in sample P3/1 only a small amount of 
COX1 remained non-acetylated, while in a single sample 
(P4/1) no acetylation occurred. As noncompliance was 
assumed, these patients were contacted and their atten-
tion was drawn to the danger of not taking or irregularly 
taking the drug. After an additional two weeks the tests 
were repeated and full effectiveness of aspirin was dem-
onstrated by the absence of non-acetylated COX1 and 
the presence of acetylated COX1 in the platelet lysate 
(see representative results on lanes P3/2 and P4/2, Fig. 1). 
According to sample size calculations the lack of aspirin 
resistance in all of the 144 patients indicated that aspirin 
is effective in more than 98 % of patients with stable cor-
onary artery disease (confidence interval 95 %). It is to be 
noted that aspirin was fully effective in diabetic patients 
and also in smokers.
The effect of aspirin on arachidonic acid induced TXB2 
production
Figure  2 demonstrates the AA induced TXB2 produc-
tion of platelets in controls and in CAD patients being 
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on long-term aspirin treatment. Aspirin drastically 
decreased the TXB2 generation, the median TXB2 pro-
duction was only 1.2  % of that measured in the control 
group. Please, note that the y axis on the plot is bro-
ken and in the low range the scale is different. Here six 
patients also had higher TXB2 generation in the range of 
43–835 pg TXB2/106 platelets, but at the second occasion 
their value returned to the range of the remaining 138 
patients. In Fig. 2 their samples are represented only with 
the results of the second determinations.
The effect of aspirin on arachidonic acid induced platelet 
activation
In accordance with the considerably decreased TXB2 pro-
duction, the extent of AA induced aggregation of platelets 
from aspirin treated patients was uniformly very low and 
no overlap between controls and patients was observed 
(Fig.  3). The median value of AA induced ATP release in 
PRP was 1.1 μmol ATP/1011 platelets (IQR: 0.9–1.4) in 
the control group, while in the PRP of all aspirin treated 
patients the amount of released ATP was below the limit of 
detection. In the case of VerifyNow Aspirin assay four ARU 
values from the patients group (2.8  %) overlapped with 
the total range of ARU values of the control group (Fig. 3). 
For this assay the manufacturer recommends 550 ARU as 
the cut off value for aspirin effect, however according to 
the results of the control group a cut off value of 585 ARU 
seems to be more appropriate. The reason for the slight dif-
ference between the other assays and the VerifyNow Aspi-
rin Assay, the latter also uses AA as agonist, is not clear. 
Maybe the detection system used in the VerifyNow Aspirin 
Assay (aggregation of fibrinogen coated beads) is responsi-
ble for the few outliers in the patient’s group.
It is to be noted that 24 % of the study group were dia-
betic patients, the CRP level was above 5 mg/L in 21 % 
Table 1 Characteristics of patient population
Mean ± SD and total range in parenthesis are shown in the case of parameters 
with normal distribution and median with interquartile range and total range 
are given for parameters with non-normal distribution
BMI body mass index, HDL-C high-density lipoprotein cholesterol, LDL-C low-
density lipoprotein cholesterol, CRP C-reactive protein, GFR glomerular filtration 
rate
Age (years) 64 ± 10 (42–85)
Male gender 67 %
BMI (kg/m2) 30 (26–33; 17–51)
Current smoker 10 %
Ever smoker 61 %
Diabetes mellitus 24 %
Triglyceride (mmol/L) 1.54 (1.1–2.1; 0.6–6.5)
Total cholesterol (mmol/L) 4.6 (3.8–5.4; 2.2–8.8)
HDL-C (mmol/L) 1.2 (1.1–1.5; 0.7–2.5)
LDL-C (mmol/L) 2.5 (2.0–3.3; 1.0–6.1)
Platelets (g/L) 237 ± 58 (100–432)
Fibrinogen (g/L) 3.7 (3.3–4.2; 2.0–7.1)
CRP (mg/L) 2.1 (0.9–4.3; 0.5–20.5)
Serum creatinine (µmol/L) 79 (68–90; 49–179)
GFR (mL/min/1.73 m2) 86 (70–91; 23–91)
Fig. 1 Detection of acetylated COX1 (acCOX1, lower panel) and 
non-acetylated COX1 (nacCOX1, upper panel) in platelet lysate of 
non-treated controls (C) and patients on aspirin treatment (P1–P4). 
Monoclonal antibodies specific to the acetylated and non-acetylated 
forms of COX1 were used in Western blotting detection system. In 
patients P3 and P4 non-compliance was presumed and the test was 
repeated after a 2 weeks period of compliance (P3/2 and P4/2). Below 
the band representing COX-1 another low intensity band cross-
reacting with both antibodies is also apparent. It very likely represents 
COX-1 isoform 2, a 37 amino acids shorter transcript variant (http://
www.ncbi.nlm.nih.gov/nuccore/18104968)
Fig. 2 Arachidonic acid induced TXB2 generation of platelets from 
controls (open square) and from patients with coronary artery disease 
being on long-term aspirin treatment (filled circle). IQR interquartile 
range
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of the patients and in spite of the clinical condition 10 % 
of them was unable to quit smoking. In none of these 
patients was impaired aspirin effect measured by any of 
the methods used in the study.
The effect of aspirin on platelets with COX2 mRNA 
expression
Out of the 56 patients investigated for the expression of 
COX2 mRNA only in 22 cases was the amount above the 
limit of detection (Fig. 4). Even in these cases the relative 
amount of COX2 mRNA was less than 0.4  % of COX1 
mRNA and with the exception of three patients this value 
was less than 0.05  %. None of the patients expressing 
COX2 mRNA in platelets showed aspirin resistance.
Discussion
So far, the direct measurement of COX1 acetylation in 
healthy volunteers taking 100  mg aspirin has been car-
ried out in two studies using different methodologies. 
Our former study measured nacCOX1 and acCOX1 by 
Western blotting technique using specific monoclonal 
antibodies [11], in another study platelet proteins were 
separated by nuPAGE then, in-gel enzymatic diges-
tion was carried out and the COX1 peptide carrying the 
Ser529 residue was determined by mass spectrometry 
[13]. One hundred and eight and twenty-four individu-
als were enrolled in the studies, respectively and in none 
of the cases was true aspirin resistance revealed. It is to 
be noted that using AA-induced platelet aggregation 
and serum TXB2 measurement Grosser et  al. [24] also 
failed to detect specific phenotype of true aspirin resist-
ance among 400 healthy volunteers. As in patients with 
CAD the occurrence of aspirin resistance has not been 
explored by detecting the acetylation of COX1 in plate-
lets, our method developed as part of basic research 
was translated to address this question in clinical set-
ting. In this study none of the 144 patients enrolled in 
the study showed impaired acetylation of platelet COX1, 
TXB2 generation, AA-induced platelet aggregation and 
ATP release were profoundly inhibited by aspirin in all 
patients. Neither diabetes nor smoking influenced the 
effectiveness of aspirin and inflammatory condition 
shown by elevated CRP also failed to influence COX1 
acetylation. This finding suggests that in patients with 
coronary artery disease, just like in healthy individuals 
aspirin resistance, if it exists at all, is a rarity.
Several factors have been suggested to influence the 
effect of aspirin in pathological conditions. Increased 
platelet turnover was presumed to release newly formed 
platelets with nacCOX1 into the circulation and produce 
Fig. 3 The results of arachidonic acid induced platelet aggregation and VerifyNow Aspirin Assay in controls (open square) and in patients with 
coronary artery disease being on long-term aspirin treatment (filled circle). IQR interquartile range
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enough TXA2 to activate platelets, even platelets with 
acCOX1 [14, 15, 25, 26]. This problem was thought par-
ticularly important in the case of enteric-coated aspirin 
administered in a single daily dose. However, important 
component of the inhibitory effect of aspirin occurs in 
the presystemic circulation [13, 27]. Furthermore, COX1 
of megakaryocytes is acetylated by aspirin and platelets 
released from megakaryocytes contain acCOX1 [28]. 
Furthermore, the finding of a persistent level of acCOX1 
throughout a 7  days interval of treatment with once 
daily 100  mg enteric-coated aspirin provides direct evi-
dence that acetylated platelets entered into the circula-
tion during this time-frame [13]. Our present finding 
demonstrating that patients on long-term aspirin contain 
more than 97.5 % COX1 in acetylated form also support 
the cumulative nature of platelet COX1 inhibition upon 
repeated daily dosing [29]. The reports on the increased 
level of COX1 acetylation 24 h after the sixth daily dose 
of aspirin as compared to the level measured 24 h after 
a single aspirin dose also indicate cumulative saturable 
acetylation of platelet COX1 [11, 13].
COX2, an isoenzyme of COX1, is also sensitive to 
the inhibitory effect of aspirin [8, 30]. However a much 
higher dose of aspirin, well above the range reached dur-
ing the prophylactic low dose aspirin therapy, is needed 
to acetylate the respective serine residue (in this case 
Ser516) [16]. This enzyme is present in megakaryocytes, 
it is expressed in young platelets [31] and its up-regula-
tion has been described in diabetes mellitus and inflam-
matory conditions [17, 32, 33]. It has been proposed that 
COX2 expression in platelets might result in the sup-
pression of aspirin effect. However, Riondino et  al. [34] 
demonstrated on 100 patients being on chronic aspi-
rin treatment by immunoblot analysis that COX2 could 
be detected only in 46 % of patients and its amount was 
markedly lower than that of COX1. By using COX2 
inhibitor CAY10404 and aspirin they also demonstrated 
that COX2 dependent TXA2 production is less than 2 %. 
Our results are in line with the latter observations. We 
found detectable amount of platelet COX2 mRNA only 
in 39  % of patients with stable coronary artery disease. 
Even in those cases in which COX2 mRNA was detected, 
its amount was incomparably lower than that of COX1 
mRNA and platelets from these patients produced a very 
low amount of TXB2 comparable to the rest of the aspi-
rin treated patients. These findings do not support the 
role of COX2 expressed in platelets in the diminished 
response to low dose aspirin therapy.
In the light of the above findings it is a question if aspi-
rin therapy should be monitored at all. In theory, muta-
tions in the COX1 gene may result in a situation in which 
aspirin is unable to acetylate the enzyme, however such 
a situation has not been reported. The results suggest 
that the effect of aspirin does not need to be controlled in 
patients with coronary artery disease, unless non-compli-
ance or drug interference is suspected. The main reason 
for the ineffectiveness of aspirin as detected by labora-
tory tests is non-compliance [35–37], testing of patients 
on aspirin therapy could provide information on their 
compliance. Non-steroid anti-inflammatory drugs may 
interfere with the effect of aspirin [38–40] and insuffi-
cient aspirin effect measured by adequate laboratory tests 
could draw the attention to such drug interference. It is 
to be emphasized that for the above purposes only meth-
ods specific to the effect of COX1 acetylation should be 
used. Among the routinely used methods these include 
AA induced platelet aggregation and secretion, the Veri-
fyNow Aspirin Assay and the measurement of serum 
TXB2 [41]. This statement is valid only for aspirin mono-
therapy, its combination with P2Y12 receptor inhibitors 
(dual antiplatelet therapy) might influence the test results 
[42]. A limitation of the study is the patient population 
that comprised of individuals with stable coronary dis-
ease. It is to be seen if the results could be extended to 
patients with acute coronary syndrome.
Conclusions
The acetylation of platelet COX1 was tested in 144 
patients with stable coronary artery disease. A direct 
method based on monoclonal antibodies against nac-
COX1 and acCOX1 failed to detect aspirin resistance 
among the patients. Similar results were obtained with 
the measurement of AA induced TXB2 production of 
platelets, with AA induced platelet aggregation and ATP 
secretion and the VerifyNow Aspirin assay. These meth-
ods are useful in detecting non-compliance and very 
likely also drug interference. COX2 mRNA was expressed 
in 39  % of 56 investigated patients in very low amount, 
but it was not related to impaired aspirin effect.
Fig. 4 COX2:COX1 mRNA ratios in the platelets of patients with 
detectable COX2 mRNA
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